Dr. Byers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
University of Texas Health Science Center at HoustonFellowship, Medical Oncology, 2006 - 2009
Baylor College of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TX State Medical License 2006 - 2026
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
WA State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2011 Jan 03
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
- A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Publications & Presentations
PubMed
- 15 citationsIdentification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer.Tomohiko Kakumu, Mitsuo Sato, Daiki Goto, Toshio Kato, Naoyuki Yogo
Cancer Science. 2017-04-01 - 748 citationsAn Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhi...Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard
Clinical Cancer Research. 2013-01-01 - 3881 citationsComprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research networkEric A. Collisson, Joshua D. Campbell, Angela N. Brooks, Alice H. Berger, William Lee
Nature. 2014-01-01
Journal Articles
- Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies Across Platinum-Resistant CancersFaye M Johnson, John V Heymach, Lauren Averett Byers, Clinical Cancer Research
Press Mentions
How Are Targeted Therapies Used in Lung Cancer Treatment?July 30th, 2024- Limited-Stage SCLC Gets a New Standard of Care with Consolidation DurvalumabJune 3rd, 2024
- New Medical Device Offered by UAMS Relieves Pain Caused by Diabetic NeuropathyAugust 7th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
